GE announces first patient dosed with new PET radiopharmaceutical

By staff writers

March 28, 2022 -- GE Healthcare announced that the first patient has been dosed in a phase III trial underway in France with a new dopamine transporter PET imaging radiopharmaceutical.

The agent is for evaluation of adult patients with suspected Parkinson's disease, and it was originally developed by French firm Zionexa, which GE's Pharmaceutical Diagnostic business acquired last year.

The company also has plans to test another dopamine transporter agent it has licensed from brain imaging firm LikeMinds in Boston for use with SPECT imaging, it said.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking